Drug Profile
Research programme: deubiquitinating enzyme modulators - Cancer Research Technology/FORMA Therapeutics
Alternative Names: DUB protein modulators - Cancer Research Technology/FORMA TherapeuticsLatest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Cancer Research Technology; FORMA Therapeutics
- Class
- Mechanism of Action Deubiquitinating enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in United Kingdom
- 09 Jul 2013 Early research in Cancer in United Kingdom (unspecified route)